Donnelly Craig 4

What Happened

• Craig Donnelly, Chief Operations Officer of Achieve Life Sciences (ACHV), received a derivative award representing 180,000 shares on January 28, 2026. The filing reports an acquisition price of $0.00 per share (derivative award), indicating no immediate cash outlay in this transaction.
• This is a compensation grant (an award), not a market purchase or sale.

Key Details

• Transaction date: January 28, 2026; Form 4 filed January 30, 2026 (appears timely).
• Instrument: Derivative award for 180,000 shares at $0.00 per share (reported as "A" — grant/award).
• Vesting: 1/4 of the award vests on the first anniversary (Jan 28, 2027), then in substantially equal monthly installments over the following 36 months (per footnote).
• Shares owned after transaction: not disclosed in the provided excerpt.
• No 10b5-1 plan, tax-withholding sale, or late filing flag reported in this excerpt.

Context

• This is a typical executive compensation grant that vests over time to align incentives; it is not an immediate purchase or sale that signals near-term market action.
• Because it is a derivative award with a vesting schedule, these shares become meaningful to ownership only as they vest; the filing does not indicate any immediate sale or cashless exercise.